Carrier erythrocytes: Recent advances, present status, current trends and future horizons

Expert Opinion on Drug Delivery

Volumn 11, Issue 3, 2014, Pages 433-447

  Zarrin, Abdolhossein ^a   Foroozesh, Mahshid ^b   Hamidi, Mehrdad ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b R and D Department   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carrier erythrocytes; Cellular drug delivery; Drug delivery; Drug targeting

Indexed keywords

DRUG; DRUG CARRIER; OXYGEN;

ANIMAL; ERYTHROCYTE; HUMAN; METABOLISM;

ANIMALS; DRUG CARRIERS; ERYTHROCYTES; HUMANS; OXYGEN; PHARMACEUTICAL PREPARATIONS;

EID: 84894426345     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.880422     Document Type: Review

References (88)

1. Hamidi M, Tajerzadeh H. Carrier erythrocytes: An overview. Drug Deliv 2003;10:9-20
2. Hamidi M, Zarrin AH, Foroozesh M, et al. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release 2007;118:145-60
3. Muzykantov VR. Drug delivery by red blood cells: Vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010;7:403-27
4. Pierige F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev 2008;60:286-95
5. Patel PD, Dand N, Hirlekar RS, Kadam VJ. Drug loaded erythrocytes: As novel drug delivery. Curr Pharm Des 2008;14:63-70
6. Biagiotti S, Paoletti MF, Fraternale A, et al. Drug delivery by red blood cells. IUBMB Life 2011;63:621-31
7. Gutierrez Millan C, Colino Gandarillas CI, Sayalero Marinero ML, Lanao JM. Cell-based drug-delivery platforms. Ther Deliv 2012;3:25-41
8. Magnani M, Pierige F, Rossi L. Erythrocytes as a novel delivery vehicle for biologics: From enzymes to nucleic acid-based therapeutics. Ther Deliv 2012;3:405-14
9. Magnani M, Chiarantini L, Vittoria E, et al. Red blood cells as an antigen-delivery system. Biotechnol Appl Biochem 1992;16:188-94
10. Millan CG, Marinero ML, Castaneda AZ, Lanao JM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release 2004;95:27-49
11. Magnani M, Casabianca A, Fraternale A, et al. Inhibition of murine AIDS by a new azidothymidine homodinucleotides. J Acquir Immun Defic Syndr Hum Retrovirol 1998;17:189-95
12. Rossi L, Brandi G, Schiavano GF, et al. Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir. AIDS Res Hum Retroviruses 1998;14:435-44
13. Franchetti P, Rossi L, Cappellacci L, et al. Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphono methoxypropyl) adenine. Antivir Chem Chemother 2001;12:151-9
14. Franchetti P, Cappellacci L, Petrelli R, et al. Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of heterodinucleotide of lamivudine and tenofovir. Nucleosides Nucleotides Nucleic Acids 2007;26:953-7
15. Rossi L, Franchetti P, Pierige F, et al. Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir. J Antimicrob Chemother 2007;59:666-75
16. Feder R, Nehushtai R, Mor A. Affinity driven molecular transfer from erythrocyte membrane to target cells. Peptides 2001;22:1683-90
17. Kwon YM, Chung HS, Moon C, et al. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release 2009;139:182-9
18. Taylor RP, Sutherland WM, Reist CJ, et al. Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment. Proc Natl Acad Sci USA 1991;88:3305-9
19. Whipple EC, Shanahan RS, Ditto AH, et al. Analysis of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice. J Immunol 2004;173:2297-306
20. Zaitsev S, Danielyan K, Murciano JC, et al. Human complement receptor type 1-mediated loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood 2006;108:1895-902
21. Murciano JC, Medinilla S, Eslin D, et al. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol 2003;21:891-6
22. Zaitsev S, Spitzer D, Murciano JC, et al. Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther 2010;33:1022-31
23. Zaitsev S, Spitzer D, Murciano JC, et al. Sustained thrombophylaxis mediated by an RBC-Targeted pro-urokinase zymogen activated at the site of clot formation. Blood 2010;115:5241-8
24. Muzykantov VR, Smirnov MD, Samokhin GP. Avidin attachment to biotinylated erythrocytes induces homologous lysis via the alternative pathway of complement. Blood 1991;78:2611-18
25. Muzykantov VR, Smirnov MD, Kalibanov AL. Avidin attachment to red blood cells via a phospholipid derivative of biotin provides complement-resistant immunoerythrocytes. J immunol Methods 1993;158:183-90
26. Muzykantov VR, Murciano JC, Taylor RP, et al. Regulation of the complement-mediated elimination of red blood cells modified by biotin and streptavidin. Anal Biochem 1996;241:109-19
27. Hamidi M, Azimi K, Mohammadi-Samani S. Co-encapsulation of a drug with a protein in erythrocytes for improved drug loading and release: Phenytoin and bovine serum albumin (BSA). J Pharm Pharm Sci 2011;14:46-59
28. Rossi L, Migliavacca B, Pierige F, et al. Prolonged islet allograft survival in diabetic mice upon macrophage depletion by clodronate-loaded erythrocytes. Transplantation 2008;85:648-50
29. Kim SH, Kim EJ, Hou JH, et al. Opsonized erythrocyte ghosts for livertargeted delivery of antisense oligodeoxynucleotides. Biomaterials 2009;30:959-67
30. Byun HM, Suh D, Yoon H, et al. Erythrocyte ghost-mediated gene delivery for prolonged and blood-Targeted expression. Gene Ther 2004;11:492-6
31. Murciano JC, Higazi AA, Cines DB, Muzykantov VR. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. J Control Release 2009;139:190-6
32. Hamidi M, Zarei N, Zarrin AH, et al. Preparation and in vitro characterization of carrier erythrocytes for vaccine delivery. Int J Pharm 2007;338:70-8
33. Banz A, Cremel M, Rembert A, Godfrin Y. In situ targeting of dendritic cells by antigen-loaded red blood cells: A novel approach to cancer immunotherapy. Vaccine 2010;28:2965-72
34. Skorokhod OA, Garmaeva TTS, Vitvitsky VM, et al. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia. Med Sci Monit 2004;10:PI55-64
35. Lejeune A, Moorjani M, Gicquaud C, et al. Nanoerythrosome, a new derivative of erythrocyte ghost: Preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res 1994;14:915-19
36. Moorijani M, Lejeune A, Gicquaud C, et al. Nanoerythrosome, a new derivative of erythrocyte ghost II: Identification of the mechanism of action. Anticancer Res 1996;16:2831-6
37. Lejeune A, Poyet P, Gaudreault RC, Gicquaud C. Nanoerythrosome, a new derivative of erythrocyte ghost III: Is phagocytosis involved in the mechanism of action?. Anticancer Res 1997;17:3599-603
38. Desilets J, Lejeune A, Mercer J, Gicquaud C. Nanoerythrosome, a new derivative of erythrocyte ghost IV: Fate of reinjected nanoerythrosomes. Anticancer Res 2001;21:1741-7
39. Pouliot R, Saint-Laurent A, Chypre C, et al. Spectroscopic characterization of nanoErythrosomes in the absence and presence of conjugated polyethyleneglycols: An FTIR and (31) P-NMR study. Biochim Biophys Acta 2002;1564:317-24
40. Chambers E, Mitragorti S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J Control Release 2004;100:111-19
41. Chambers E, Mitragotri S. Long circulating nanoparticles via adhesion on red blood cells: Mechanism and extended circulation. Exp Biol Med (Maywood) 2007;232:958-66
42. Hall SS, Mitragorti S, Daugherty PS. Identification of peptide ligands facilitating nanoparticle attachment to erythrocytes. Biotechnol Prog 2007;23:749-54
43. Staedtke V, Brahler M, Muller A, et al. In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosuspension in red blood cells. Small 2010;6:96-103
44. Hamidi M, Rafiei P, Azadi A, Mohammadi-Samani S. Encapsulation of valproate-loaded hydrogel nanoparticles in intact human erythrocytes: A novel nano-cell composite for drug delivery. J Pharm Sci 2011;100:1702-11
45. Johnson KM, Tao JZ, Kennan RP, Gore JC. Gadolinium-bearing red cells as blood pool MRI contrast agents. Magn Reson Med 1998;40:133-42
46. Brahler M, Georgieva R, Buske N, et al. Magnetite-loaded carrier erythrocytes as contrast agents for magnetic resonance imaging. Nano Lett 2006;6:2505-9
47. Antonelli A, Sfara C, Mosca L, et al. New biomimetic constructs for improved in vivo circulation of superparamagnetic nanoparticles. J Nanosci Nanotechnol 2008;8:2270-8
48. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012;64:1394-416
49. Flower R, Peiretti E, Magnani M, et al. Observation of erythrocyte dynamics in the retinal capillaries and choriocapillaris using ICG-loaded erythrocyte ghost cells. Invest Ophthalmol Vis Sci 2008;49:5510-16
50. Bahmani B, Bacon D, Anvari B. Erythrocyte-derived photo-Theranostic agents: Hybrid nano-vesicles containing indocyanine green for near infrared imaging and therapeutic applications. Sci Rep 2013;3:2180
51. Magnani M, Rossi L, Fraternale A, et al. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther 2002;9:749-51
52. Doshi N, Zahr AS, Bhaskar S, et al. Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA 2009;106:21495-9
53. Beutler E, Dale GL, Guinto DE, Kuhl W. Enzyme replacement therapy in Gaucher's disease: Preliminary clinical trial of a new enzyme preparation. Proc Natl Acad Sci USA 1977;74:4620-3
54. Bax BE, Bain MD, Fairbanks LD, et al. Carrier erythrocyte entrapped adenosine deaminase therapy in adenosine deaminase deficiency. Adv Exp Med Biol 2000;486:47-5055
55. Kravtzoff R, Colombat PH, Desbois I, et al. Tolerance evaluation of L-Asparaginase loaded in red blood cells. Eur J Clin Pharmacol 1996;51:221-5
56. Fiorelli G, Fargion S, Piperno A, et al. Transfusion of thalasemic patients with desferrioxamine loaded standard red blood cell units. Adv Biosci (series) 1987;67:47-54
57. Moran NF, Bain MD, Muqit MM, Bax BE. Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology 2008;71:686-8
58. Rossi L, Serafini S, Cenerini L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol Appl Biochem 2001;33:85-9
59. Rossi L, Castro M, D'Orio F, et al. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cell Mol Dis 2004;33:57-63
60. Annese V, Latiano A, Rossi L, et al. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - A pilot uncontrolled study. Am J Gastroenterol 2005;100:1370-5
61. Castro M, Knafelz D, Rossi L, et al. Periodic treatment with autologous erythrocytes loaded dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: Case report. J Pediatr Gastroenterol Nutr 2006;42:313-15
62. Annese V, Latiano A, Rossi L, et al. The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2006;10:27-31
63. Castro M, Rossi L, Papadatou B, et al. Long-Term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent crohn disease. J Pediatr Gastroenterol Nutr 2007;44:423-6
64. Lizano C, Weissig V, Torchilin VP, et al. In vivo biodistribution of erythrocytes and polyethyleneglycolphosphatidylethanolamine micelles carrying antitumor agent dequalinium. Eur J Pharm Biopharm 2003;56:153-7
65. Lynch WE, Sartiano GP, Ghaffar A. Erythrocytes as carriers of chemotherapeutic agents for targeting the reticuloenothelial system. Am J Hematol 1980;9:249-59
66. Skorokhod OA, Kulikova EV, Galkina NM, et al. Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded erythrocytes. Haematologica 2007;92:570-1
67. Yuan SH, Ge WH, Huo J, Wang XH. Slow release properties and liver-Targeting characteristics of methotrexate erythrocyte carriers. Fundam Clin Pharmacol 2009;23:189-96
68. Wang GP, Guan YS, Jin XR, et al. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites. J Gastroenterol Hepatol 2010;25:985-90
69. Ganguly K, Murciano JC, Westrick R, et al. The glycocalyx protects erythrocytebound tissue-Type plasminogen activator from enzymatic inhibition. J Pharmacol Exp Ther 2007;321:158-64
70. Ganguly K, Krasik T, Medinilla S, et al. Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther 2005;312:1106-13
71. Armstead WM, Ganguly K, Riley J, et al. RBC-coupled tPA prevents whereas tPA aggravates JNK MAPK-mediated impairment of ATP- And Ca-sensitive K channel-mediated cerebrovasodilation after cerebral photothrombosis. Transl Stroke Res 2012;3:114-21
72. Fraternale A, Casabianca A, Orlandi C, et al. Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model. Antiviral Res 2002;56:263-72
73. Fraternale A, Paoletti MF, Casabianca A, et al. Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. J Drug Target 2009;17:278-85
74. Bax BE, Bain MD, Fairbanks LD, et al. A 9-year evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-Type ADA deficiency. Eur J Haematol 2007;79:338-48
75. Bax BE, Bain MD, Fairbanks LD, et al. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase. Br J Haematol 2000;109:549-54
76. Liu Y, Guan H, Beckett TL, et al. In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes. Peptides 2007;28:2348-55
77. Kosenko EA, Venediktova NI, Kudryavtsev AA, et al. Encapsulation of glutamine synthetase in mouse erythrocytes: A new procedure for ammonia detoxification. Biochem Cell Biol 2008;86:469-76
78. Murray AM, Pearson IF, Fairbanks LD, et al. The mouse immune response to carrier erythrocyte entrapped antigens. Vaccine 2006;24:6129-39
79. Hamidi M, Zarei N, Zarrin AH, et al. Preparation and validation of carrier erythrocytes loaded by bovine serum albumin as a model antigen. Drug Deliv 2007;14:295-300
80. Corinti S, Chiarantini L, Dominici S, et al. Erythrocytes deliver Tat to interferon-gamma-Treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro. J Leukoc Biol 2002;71:652-8
81. Dominici S, Laguardia ME, Serafini G, et al. Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. Vaccine 2003;21:2073-81
82. Hamid M, Zarrin AH, Foroozesh M, et al. Preparation and in vitro evaluation of carrier erythrocytes for RES-Targeted delivery of interferon-Alpha 2b. Int J Pharm 2007;341:125-33
83. Alanazi FK, Haria Gel-D, Maqboul A, et al. Biochemically altered human erythrocytes as a carrier for targeted delivery of primaquine: An in vitro study. Arch Pharm Res 2011;34:563-71
84. Shavi GV, Doijad RC, Deshpande PB, et al. Erythrocytes as carrier for prednisolone: In vitro and in vivo evaluation. Pak J Pharm Sci 2010;23:194-200
85. Harisa Gel-D, Ibrahim MF, Alanazi FK. Characterization of human erythrocytes as potential carrier for pravastatin: An in vitro study. Int J Med Sci 2011;8:222-30
86. Franternale A, Casabianca A, Rossi L, et al. Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections. J Antimicrob Chemother 2003;52:551-4
87. Rossi L, Brandi G, Schiavano GF, et al. Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. AIDS Res Hum Retroviruses 1999;15:345-53
88. Serafini S, Rossi L, Antonelli A, et al. Drug delivery through phagocytosis of red blood cells. Transfus Med Hemother 2004;31:92-101